Skip to main content

Ixinity FDA Approval History

FDA Approved: Yes (First approved April 29, 2015)
Brand name: Ixinity
Generic name: coagulation factor IX (recombinant)
Company: Emergent BioSolutions Inc.
Treatment for: Hemophilia B

Ixinity (coagulation factor IX (recombinant)) is a clotting factor IX therapy indicated to prevent bleeding in patients with hemophilia B.

Development timeline for Ixinity

Apr 30, 2015Approval Emergent BioSolutions Announces FDA Approval of Ixinity [coagulation factor IX (recombinant)] for Hemophilia B
Apr 18, 2012Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.